An updated version of Exact Sciences' key product just got regulatory approval. That could help the healthcare stock stage a comeback.

Famed innovation investor Cathie Wood is attempting to stage a comeback after a somewhat sluggish past few years. Though the Ark funds may be down and trailing the market, Wood isn’t letting volatility stop her from continuing to make bold and,

While Cathie Wood, chief executive of Ark Investment Management, specializes in small- and midcap technology stocks, sometimes she goes for the megacaps. The idea presumably is to provide ballast for her funds, which consist mostly of riskier stocks. Sometimes she’ll even buy when the stocks are rising, and that’s what she did Tuesday.

Cathie Wood, the CEO of Ark Invest, has several AI stocks in her investment management firm's actively managed ETFs. One of them is Recursion Pharmaceuticals ( RXRX -4.57%), a company looking to use AI to revolutionize the drug development process. Should investors follow Cathie Wood's lead?

Nubank, Latin America’s largest fintech bank, has the ability to grow globally. A recent pullback in its parent company’s shares offers an attractive entry point.